The FDA updated the labeling for rilipivirine (Edurant) for the treatment of HIV-positive pregnant patients who were on stable treatment prior to conception and who are virologically suppressed.
Laurie Toich, Associate Editor, Specialty Pharmacy Times
Advertisement
Articles by Laurie Toich, Associate Editor, Specialty Pharmacy Times
Advertisement
Latest Updated Articles
FDA Updates HIV Drug Label to Include Dosing for Pregnant PatientsPublished: February 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Is Berberine Nature’s GLP-1?
2
Glucodensity Analysis Enhances CGM Accuracy for Detecting Cystic Fibrosis–Related Diabetes
3
Because Ned Said: America’s Growing Pharmacy Deserts Are Leaving Patients High and Dry
4
Experts Highlight Key Sessions and Emerging Topics from The Menopause Society 2025 Annual Meeting
5
